The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status.
 
Riccardo Lobefaro
No Relationships to Disclose
 
Giuseppe Viscardi
No Relationships to Disclose
 
Raimondo Di Liello
No Relationships to Disclose
 
Giacomo Massa
No Relationships to Disclose
 
Maria Lucia Iacovino
No Relationships to Disclose
 
Francesca Sparano
No Relationships to Disclose
 
Roberto Ferrara
No Relationships to Disclose
 
Diego Signorelli
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD
 
Claudia Proto
Honoraria - BMSi; Lilly; MSD
Travel, Accommodations, Expenses - BMSi; Lilly; MSD
 
Arsela Prelaj
No Relationships to Disclose
 
Giulia Galli
No Relationships to Disclose
 
Alessandro De Toma
No Relationships to Disclose
 
Marta Brambilla
No Relationships to Disclose
 
Monica Ganzinelli
No Relationships to Disclose
 
Benedetta Trevisan
No Relationships to Disclose
 
Achille Bottiglieri
No Relationships to Disclose
 
Filippo G. De Braud
Honoraria - Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Ignyta; Incyte; Nerviano Medical Sciences; Octimet; Pierre Fabre; Roche; Sanofi; Teofarma
Speakers' Bureau - Menarini
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Floriana Morgillo
Consulting or Advisory Role - Lilly; MSD
Research Funding - AstraZeneca
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Incyte; Inivata; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Giuseppe Lo Russo
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD